These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32189406)

  • 1. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics.
    Ray U; Raul SK; Gopinatha VK; Ghosh D; Rangappa KS; Mantelingu K; Raghavan SC
    Mol Carcinog; 2020 Jun; 59(6):618-628. PubMed ID: 32189406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
    Vartak SV; Swarup HA; Gopalakrishnan V; Gopinatha VK; Ropars V; Nambiar M; John F; Kothanahally SKS; Kumari R; Kumari N; Ray U; Radha G; Dinesh D; Pandey M; Ananda H; Karki SS; Srivastava M; Charbonnier JB; Choudhary B; Mantelingu K; Raghavan SC
    FEBS J; 2018 Nov; 285(21):3959-3976. PubMed ID: 30230716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
    Greco GE; Matsumoto Y; Brooks RC; Lu Z; Lieber MR; Tomkinson AE
    DNA Repair (Amst); 2016 Jul; 43():18-23. PubMed ID: 27235626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation.
    Gopalakrishnan V; Sharma S; Ray U; Manjunath M; Lakshmanan D; Vartak SV; Gopinatha VK; Srivastava M; Kempegowda M; Choudhary B; Raghavan SC
    Mol Carcinog; 2021 Sep; 60(9):627-643. PubMed ID: 34192388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining.
    Manjunath M; Choudhary B; Raghavan SC
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1341. PubMed ID: 33496064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression.
    Srivastava M; Nambiar M; Sharma S; Karki SS; Goldsmith G; Hegde M; Kumar S; Pandey M; Singh RK; Ray P; Natarajan R; Kelkar M; De A; Choudhary B; Raghavan SC
    Cell; 2012 Dec; 151(7):1474-87. PubMed ID: 23260137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
    Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing.
    Vartak SV; Raghavan SC
    FEBS J; 2015 Nov; 282(22):4289-94. PubMed ID: 26290158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pluronic copolymer encapsulated SCR7 as a potential anticancer agent.
    John F; George J; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Faraday Discuss; 2015; 177():155-61. PubMed ID: 25608025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NHEJ inhibitor SCR7 and its different forms: Promising CRISPR tools for genome engineering.
    Ray U; Vartak SV; Raghavan SC
    Gene; 2020 Dec; 763():144997. PubMed ID: 32783992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
    Soni A; Siemann M; Pantelias GE; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of pluronic copolymer micelle encapsulated SCR7 against cancer cell proliferation.
    John F; George J; Vartak SV; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Macromol Biosci; 2015 Apr; 15(4):521-34. PubMed ID: 25515310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of mercaptopyrimidine-based small molecules as inhibitors of nonhomologous DNA end joining.
    Ray U; Gopinatha VK; Sharma S; Goyary L; Choudhary B; Mantelingu K; Rangappa KS; Raghavan SC
    FEBS J; 2023 Feb; 290(3):796-820. PubMed ID: 36048168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small molecule inhibitor of the DNA repair protein Ku70/80.
    Weterings E; Gallegos AC; Dominick LN; Cooke LS; Bartels TN; Vagner J; Matsunaga TO; Mahadevan D
    DNA Repair (Amst); 2016 Jul; 43():98-106. PubMed ID: 27130816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.
    Maruyama T; Dougan SK; Truttmann MC; Bilate AM; Ingram JR; Ploegh HL
    Nat Biotechnol; 2015 May; 33(5):538-42. PubMed ID: 25798939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of ligase IV leads to reduced NHEJ, accumulation of DNA damage, and can sensitize cells to cancer therapeutics.
    Kumari N; Antil H; Kumari S; Raghavan SC
    Genomics; 2023 Nov; 115(6):110731. PubMed ID: 37871849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA ligase IV and artemis act cooperatively to suppress homologous recombination in human cells: implications for DNA double-strand break repair.
    Kurosawa A; Saito S; So S; Hashimoto M; Iwabuchi K; Watabe H; Adachi N
    PLoS One; 2013; 8(8):e72253. PubMed ID: 23967291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of novel ligase I inhibitors.
    Pandey M; Kumar S; Goldsmith G; Srivastava M; Elango S; Shameem M; Bannerjee D; Choudhary B; Karki SS; Raghavan SC
    Mol Carcinog; 2017 Feb; 56(2):550-566. PubMed ID: 27312791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining.
    Wang H; Rosidi B; Perrault R; Wang M; Zhang L; Windhofer F; Iliakis G
    Cancer Res; 2005 May; 65(10):4020-30. PubMed ID: 15899791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.